Compare ADMA Biologics Inc (ADMA) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Yum China Holdings Inc — how do they compare? ADMA Biologics Inc trades at $9.87 (market cap $2.22B), while Yum China Holdings Inc trades at $47.69 (market cap $16.28B). The key difference: Yum China Holdings Inc is far larger — about 7.3× ADMA Biologics Inc's market cap, and Yum China Holdings Inc pays a 2.44% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | YUMC | |
|---|---|---|
Market Cap | $2.22B | $16.28B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $57.95 |
52-Week Low | $7.60 | $40.18 |
Enterprise Value | $2.29B | $17.19B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.83, up 0.82% today, with strong profitability metrics including a 32.98% net income margin and 41.9% ROE. Recent earnings show mixed results, with a beat in Q4 2025 but misses in Q1 and Q2 2026. Technical indicators are bullish overall, though RSI levels suggest overbought conditions. The stock faces significant legal headwinds from multiple securities fraud class actions filed in August 2026.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but legal risks and recent earnings misses pose near-term challenges. Upside potential exists if the company can maintain profitability and resolve litigation, while downside risks include prolonged legal proceedings and execution missteps.
YUMC trades at $47.77, down 0.87% today, with a bullish technical signal from moving averages and strong fundamental performance. The company reported Q2 2026 EPS of $0.70, beating estimates, and revenue growth of 13% year-over-year. Recent completion of the Pizza Hut brand acquisition in Mainland China for $1.2 billion enhances strategic control and potential margin expansion.
Outlook remains positive with consistent earnings beats and analyst consensus favoring a buy rating. Key risks include macroeconomic headwinds in China and integration challenges from the acquisition. The stock offers growth potential with a reasonable P/E of 17.43 and a projected 26.2% upside based on Wall Street targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
